AI-Automated Clinical Decision Support at the Point of Care
AI-guided platforms for spinal needle intervention and musculoskeletal diagnostics — purpose-built to accelerate clinical decision-making, standardize procedural outcomes, and reduce operator variability at the point of care. Where unmet need meets ready adoption.
THE CHALLENGE
Key Critical Gaps in Healthcare Delivery
Healthcare systems worldwide face procedural challenges and diagnostic bottlenecks that delay treatment, increase costs, and compromise patient outcomes.
Emergency Medicine Delays
70%+ of extremity fracture cases are simple rule-outs. Patients still wait hours for radiology—tying up resources and delaying treatment decisions.
ED hours wasted annually
Procedure Complications
Neuraxial anesthesia procedures rely on landmark palpation, leading to variable success rates and increased patient risk, especially in challenging anatomies.
%
First-attempt failure rate in challenging anatomy
Resource Constraints
Rural and underserved facilities lack access to advanced imaging, forcing transfers and delaying care for vulnerable patient populations.
Americans in rural areas with limited imaging access
Our Solution
Scalable Decision Intelligence
Faster, more confident clinical decisions at the point of care. RIVANNA’s AI-powered platforms automate complex anatomical analysis within clinician-friendly workflows, reducing variability and supporting consistent outcomes across care settings.
A Platform Built for Clinical Impact
- AI-Automated Imaging — Removes operator dependency with automated acquisition and analysis, enabling high-quality results with minimal training
- SafeTrack™ Technology — Smart sensor technology overlays real-time needle tip position and trajectory on the ultrasound display
- Dual-Array™ Technology — Patented multi-angle probe transmits converging sound waves along the needle trajectory for significantly improved in-plane visibility
- 3D Volumetric Imaging — Proprietary transducer technology captures complete anatomical context in a single acquisition
- Portable Form Factor — Designed for bedside deployment in emergency, surgical, and ambulatory settings
Deep Learning Core
Neural networks trained on proprietary clinical datasets
Robotic 3D Transducer
Gel-free automated acquisition via patented volumetric transducer technology
Edge + Cloud Computing
Real-time on-device processing with cloud connectivity for fleet analytics and continuous AI improvement
Connected Clinical Workflow
Seamless EMR and DICOM integration with device-level analytics driving operational insights
PRODUCT PIPELINE
One Platform. Two Breakthrough Products.
A unified AI imaging architecture powers two purpose-built product assets — procedural guidance for neuraxial anesthesia and point-of-care fracture care in emergency medicine — maximizing R&D leverage and market opportunity.
AI Procedure Guidance — Neuraxial Anesthesia
Next-Generation Spinal Navigation
AI FRACTURE CARE — EMERGENCY MEDICINE
AI-Powered Bedside Fracture Triage
VALIDATION & TRACTION
Validated by Government Partners, Regulators & Clinical Evidence
Government Validation
NIH federal validation of clinical and commercial viability, accelerating development.
Regulatory Pathway
FDA clearance secured for Accuro 3S device and consumables, with SafeTrack™ needle tracking and fracture platform submissions pending.
Clinical Studies
8 clinical sites nationwide, 1,200+ patients enrolled. Peer-reviewed publication in Journal of Emergency Medicine (2026).
Market Access & Reimbursement
ICD-10-PCS code pending; partnering with major medical societies to validate CPT coding pathways.
Investment Thesis
Why RIVANNA
01
Platform Technology
Core AI and 3D ultrasound IP enables expansion across multiple clinical applications with shared R&D investment.
02
De-Risked Development
Key technical and regulatory milestones funded through non-dilutive awards delivers significant leverage on equity investment.
03
Massive Market Opportunity
Combined TAM of $3.4B+ across neuraxial guidance and fracture detection, with clear expansion roadmap.
04
Regulatory Clarity
Defined FDA 510(k) pathways with pre-submission engagement completed. Experienced regulatory team with prior device clearances.
05
Proven Leadership
Experienced medtech team with track record from GE Healthcare, Philips, and successful device development.
06
Strategic Timing
AI in medical imaging at inflection point. First-mover advantage in AI-powered point-of-care diagnostics.
AI algorithms: 1 FDA‑cleared & 2 in development
FDA clearances
Global patents & patents pending
Proprietary datasets from 1,200 subjects across 8 sites nationwide
Join Us in Transforming Point-of-Care Diagnostics
We’re seeking strategic partners and investors who share our vision for AI-powered clinical decision-support platforms. Let’s discuss how RIVANNA fits your portfolio.
Latest News
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FUNDING & SOCIETY PARTNERS
Sources: ~70% non-fracture rate — A conservative floor, actual rates range 71–82% across anatomical regions (Gordon et al., Am J Emerg Med, 2021). ~20M wasted hours — Based on 5.5M annual ED visits for extremity injuries (Ootes 2012; Albright 2022, NEISS data), average ED time of 4.5 hours (ACEP/RIVANNA 2022; n = 7,139), and a mid-range non-fracture rate of 82% across anatomical regions (Gordon et al., 2021). 4.5 hrs — RIVANNA / ACEP Focus Group, 2022. 68% — Chin KJ et al., Anesthesiology, 2011;115(1):94–101. 60M+ — U.S. GAO; CMS.